Immune cell populations that are tumor specific have a much stronger tumor killing ability when compared to immune cells from blood, therefore, through the removal of potentially active T cells, such as CD4+ and CD8+ from an immunosuppressive environment and their expansion in a permissive in vitro environment, the aim of TILs therapy is to restore anti-tumor immunity. Here, CD8A is linked to neoplasm.